Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Just thinking about pain alters brain activity, study finds

NCT ID NCT07407595

Knowledge-focused Sponsor: Universite du Littoral Cote d'Opale Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study looks at how the mere expectation of pain—without any actual pain—affects the brain's ability to send signals to muscles. Forty-four healthy adults will receive an inert cream and be told either that it may cause pain or that it is inactive. Researchers will measure brain-to-muscle communication using a non-invasive technique called transcranial magnetic stimulation (TMS). The goal is to understand how pain-related expectations influence brain function, which could help prevent movement problems in people with chronic pain.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this research could point toward better ways to prevent movement problems linked to chronic pain by understanding how expectations affect the brain.
What could go wrong
This is a small, early-stage study in healthy adults, not patients. It measures brain activity, not a treatment, so direct benefits are far off.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 44 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2026

Expected to finish

Jul 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged 18 to 65 years. * No current pain at the time of inclusion and no pain episode or injury associated with pain within the past 3 months. * Ability to understand spoken and written French sufficient to follow study procedures. * Written informed consent obtained prior to participation. * Subjects affiliated with or receiving social security benefits Exclusion Criteria: * History of psychiatric disorders (including intellectual disability or severe cognitive, behavioral, or affective impairment) that could interfere with understanding the study or providing informed consent. * History of neurological disorders, including epilepsy, stroke, brain or spinal cord surgery, or any neurological disease affecting motor or sensory function. Inability to provide informed consent (e.g., dementia, significant hearing impairment, insufficient language proficiency). * Any pain condition within the past 3 months, regardless of origin. * Recent musculoskeletal injury or surgery within the past 3 months. * Contraindications to transcranial magnetic stimulation (TMS), including a history of epilepsy or the presence of intracranial metallic objects, cochlear implants, or other non-removable metallic implants in or near the head. * Use of analgesic or psychotropic medications. * Individuals under legal guardianship or curatorship. * Pregnant or breastfeeding women. * Presence of a cardiac pacemaker or other implanted electronic medical device. * Known allergy or history of skin reaction to any component of the inert cream used in the study (Medicafarm® Neutre Premium Longue Glisse).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Kinesiophobia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Kinesiophobia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Kinesiophobia Nocebo effect

Contacts and locations

Locations

  • Eurasport

    Loos, Nord, 59120, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.